Reference health
The role of pharmacogenetics in capecitabine efficacy and toxicity
65/65 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
5 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 65 checked references that resolve
resolves10.1007/s10120-013-0297-z
Optimal chemotherapy for advanced gastric cancer: is there a global consensus?
resolves10.1007/s12032-011-9958-0
5-Fluorouracil or capecitabine in the treatment of advanced colorectal cancer: a pooled-analysis of randomized trials
resolves10.1093/annonc/mdp047
Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer
resolves10.1016/j.clbc.2012.10.002
Making Capecitabine Targeted Therapy for Breast Cancer: Which is the Role of Thymidine Phosphorylase?
resolves10.1111/bcp.12449
Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5‐fluorouracil: a meta‐analysis of published trials
resolves10.1016/j.ctrv.2013.03.005
Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: A systematic review of incidence, manifestations and predisposing factors
resolves10.1016/j.clbc.2011.06.005
Dose-Adjusting Capecitabine Minimizes Adverse Effects While Maintaining Efficacy: A Retrospective Review of Capecitabine for Metastatic Breast Cancer
resolves10.1016/j.ejca.2015.10.013
Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care
resolves10.2217/pgs.11.72
Dihydropyrimidine Dehydrogenase Gene as a Major Predictor of Severe 5-Fluorouracil Toxicity
resolves10.1046/j.1365-2125.2003.01765.x
Population pharmacokinetics and concentration–effect relationships of capecitabine metabolites in colorectal cancer patients
resolves10.1038/clpt.2013.172
Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing
resolves10.1124/jpet.104.081265
Hydrolysis of Capecitabine to 5′-Deoxy-5-fluorocytidine by Human Carboxylesterases and Inhibition by Loperamide
resolves10.1159/000074480
Forced Expression of Cytidine Deaminase Confers Sensitivity to Capecitabine
resolves10.1517/17425255.2015.985648
Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs
resolves10.1007/s00280-008-0889-1
Early severe toxicities after capecitabine intake: possible implication of a cytidine deaminase extensive metabolizer profile
resolves10.1200/JCO.2011.37.9289
Sudden Death Related to Toxicity in a Patient on Capecitabine and Irinotecan Plus Bevacizumab Intake: Pharmacogenetic Implications
resolves10.1007/s002800050043
Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients
resolves10.1111/j.1365-2125.2008.03159.x
Candidate mechanisms for capecitabine‐related hand–foot syndrome
resolves10.1016/j.gene.2013.09.063
Folate: Metabolism, genes, polymorphisms and the associated diseases
resolves10.1158/1535-7163.MCT-08-0219
<i>Thymidylate synthase</i>gene variations: predictive and prognostic markers
resolves10.1634/theoncologist.2010-0261
Part 4: Pharmacogenetic Variability in Anticancer Pharmacodynamic Drug Effects
resolves10.2217/pgs.13.118
Current Approaches for
<i>TYMS</i>
Polymorphisms and their Importance in Molecular Epidemiology and Pharmacogenetics
resolves10.1158/1078-0432.CCR-06-0320
Pharmacogenetics of Capecitabine in Advanced Breast Cancer Patients
resolves10.1093/annonc/mdr445
The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer
resolves10.1002/ijc.29694
Increased risk of severe fluoropyrimidine-associated toxicity in patients carrying a G to C substitution in the first 28-bp tandem repeat of the thymidylate synthase 2R allele
resolves10.1016/j.ejca.2015.11.008
Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time
resolves10.1200/JCO.2015.63.1325
Upfront Genotyping of <i>DPYD</i>*<i>2A</i> to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis
resolves10.1007/s00280-007-0493-9
Functional study of the 830C>G polymorphism of the human carboxylesterase 2 gene
resolves10.1007/s10549-013-2516-z
Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer
resolves10.2217/pgs.13.56
<i>CDA</i>
Gene Polymorphisms and Enzyme Activity: Genotype–phenotype Relationship in an Italian–Caucasian Population
resolves10.1007/s003840100358
Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer
resolves10.1007/s12094-012-0979-8
Polymorphism of TS 3′-UTR predicts survival of Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel
resolves10.1007/s00280-015-2698-7
Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy
resolves10.1093/annonc/mdq572
Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer
resolves10.1158/1078-0432.CCR-07-0425
Thymidylate Synthase and Methylenetetrahydrofolate Reductase Gene Polymorphisms and Toxicity to Capecitabine in Advanced Colorectal Cancer Patients
resolves10.1158/1078-0432.CCR-10-2209
Relationship between Single Nucleotide Polymorphisms and Haplotypes in
<i>DPYD</i>
and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer
resolves10.2174/138920008784220646
A Carboxylesterase 2 Gene Polymorphism as Predictor of Capecitabine on Response and Time to Progression
resolves10.1634/theoncologist.2014-0379
Standard Versus Continuous Administration of Capecitabine in Metastatic Breast Cancer (GEICAM/2009-05): A Randomized, Noninferiority Phase II Trial With a Pharmacogenetic Analysis
resolves10.1007/s00280-009-0947-3
Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin
resolves10.1007/s00432-012-1183-5
Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine
resolves10.1002/cncr.26737
Identification of novel germline polymorphisms governing capecitabine sensitivity
resolves10.1097/FPC.0000000000000119
Clinical validation study of genetic markers for capecitabine efficacy in metastatic colorectal cancer patients
resolves10.18632/oncotarget.3289
Variants in<i>CDA</i>and<i>ABCB1</i>are predictors of capecitabine-related adverse reactions in colorectal cancer
resolves10.1200/JCO.2013.51.1857
Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis
resolves10.1158/1078-0432.CCR-10-1741
A Polymorphism in the <i>Cytidine Deaminase</i> Promoter Predicts Severe Capecitabine-Induced Hand-Foot Syndrome
resolves10.1007/s00280-015-2872-y
Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction
resolves10.1038/bjc.2013.262
Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity
resolves10.1038/sj.bjc.6605595
Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis
resolves10.1016/S1470-2045(15)00286-7
Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data
resolves10.1007/s00280-010-1282-4
DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity
resolves10.1016/j.ygyno.2006.09.002
Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: A gynecologic oncology group study
resolves10.1093/annonc/mdp336
EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer
resolves10.1158/1078-0432.1226.11.3
UGT1A7 and UGT1A9 Polymorphisms Predict Response and Toxicity in Colorectal Cancer Patients Treated with Capecitabine/Irinotecan
The 5 references without a DOI — listed, not checked
no DOI — not checkedImmunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines
no DOI — not checkedA candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS
no DOI — not checkedPolymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer
no DOI — not checkedReply to T. Magnes et al.
no DOI — not checkedPharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1016/j.ctrv.2016.08.001"><img src="https://citestamp.com/citestamped/10.1016/j.ctrv.2016.08.001/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1016/j.ctrv.2016.08.001)